Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Budesonide + beclomethasone is a combination of two inhaled corticosteroids, both widely used for the long-term management and control of asthma. Each component acts as a synthetic glucocorticoid with potent anti-inflammatory properties. Budesonide and beclomethasone work by binding to the glucocorticoid receptor in airway cells, suppressing inflammatory gene expression, reducing airway hyperresponsiveness, and decreasing the release of pro-inflammatory mediators such as cytokines, histamine, leukotrienes, and eicosanoids[5][6][7][8]. Both drugs are indicated for maintenance therapy in asthma but are not intended for acute relief of bronchospasm. While each is commonly combined with bronchodilators (such as formoterol) in marketed products[1][2], there is no evidence that a fixed-dose combination product containing only budesonide and beclomethasone exists or is approved; this entry describes their theoretical or compounded use together.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide + beclomethasone.